NCT02106130

A Drug Interaction Study of Mosapride and Rebamipide

A Randomized, Open-label, Multiple Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Mosapride Citrate and Rebamipide After Oral Administration in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: IlDong Pharmaceutical Co Ltd · Industry
• Sex: All
• Age: 20 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The investigators investigate the potential pharmacokinetic drug-drug interaction between Mosapride citrate 5 mg and Rebamipide 100 mg in healthy male volunteers who receive Mosapride citrate 5 mg, Rebamipide 100 mg, and both together in a 2 period repeatedly.

Detailed description

To evaluate the safety, drug-tolerance, pharmacokinetics of Mosapride citrate 5 mg or Rebamipide 100 mg monotherapy or Mosapride citrate 5 mg and Rebamipide 100 mg combination in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Rebamipide	oral administration, 3 times/day
DRUG	Mosapride citrate	oral administration, 3 times/day

Timeline

• Start date: 2013-05-01
• Primary completion: 2013-06-01
• Completion: 2013-08-01
• First posted: 2014-04-08
• Last updated: 2014-04-08

Locations

1 site across 1 country: South Korea